Guerbet
Clinical trials sponsored by Guerbet, explained in plain language.
-
Glue injection trial aims to shut down dangerous blood vessel growths
Disease control CompletedThis study tested the safety and effectiveness of a procedure that uses a special oil (Lipiodol) mixed with surgical glue to block off abnormal blood vessels. The procedure, called embolization, was performed on 132 adults with conditions like hemangiomas, angiosarcoma, or arteri…
Phase: PHASE4 • Sponsor: Guerbet • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
Trial tests new dye to sharpen MRI pictures
Diagnosis CompletedThis study tested a new dye (gadopiclenol) injected during MRI scans to see if it helps doctors see body lesions more clearly than scans without dye or with a standard dye. It involved 324 patients with known or suspected lesions who each received two MRI scans with different dye…
Phase: PHASE3 • Sponsor: Guerbet • Aim: Diagnosis
Last updated Apr 04, 2026 05:06 UTC
-
New brain scan dye aims for sharper images
Diagnosis CompletedThis trial tested a new contrast dye called gadopiclenol to see if it makes MRI scans of the brain clearer and more detailed. It involved 260 patients with known or suspected brain lesions, like tumors, who each received two MRI scans with different dyes for comparison. The main …
Phase: PHASE3 • Sponsor: Guerbet • Aim: Diagnosis
Last updated Apr 02, 2026 14:57 UTC
-
Clearer brain scans: new agent shows promise for tumor detection
Diagnosis CompletedThis completed trial tested whether a new MRI contrast agent called Elucirem could produce clearer images of brain tumors compared to an existing agent called Dotarem. The study involved 138 adults with primary or recurrent brain gliomas who underwent specialized MRI scans. Resea…
Phase: PHASE3 • Sponsor: Guerbet • Aim: Diagnosis
Last updated Mar 30, 2026 14:34 UTC
-
First look: testing MRI dye safety in babies
Knowledge-focused CompletedThis study aimed to understand how a new contrast agent (a special dye) for MRI scans is processed by the body in very young children. It involved 36 infants under 2 years old who needed an MRI. Researchers gave a single dose and took blood samples to measure how long the agent s…
Phase: PHASE2 • Sponsor: Guerbet • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC